Randomized trial · people
Retatrutide: less hunger and overeating vs placebo at higher doses
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In adults with type 2 diabetes, the higher retatrutide doses in this trial went along with less reported hunger and overeating, and people who reported these changes tended to lose more weight.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 275
- Published
- 2025
- Journal
- Diabetes Obes Metab
What they tested
The team wanted to know whether retatrutide changes self-reported appetite and eating behavior in adults with type 2 diabetes more than placebo or dulaglutide, and whether those changes track with weight loss.
How the study was done
This was a planned exploratory look at a randomized, placebo-controlled phase 2 trial in 275 adults with type 2 diabetes. Each week for up to 36 weeks, people received one of four retatrutide doses (from 0.5 mg up to 12 mg), dulaglutide at 1.5 mg, or placebo (a dummy treatment), and they filled in two questionnaires on appetite and eating habits.

Model. Individual results vary.
What they found
At week 24, people in the retatrutide 4 mg and higher arms reported bigger drops in overall appetite, hunger and how much food they expected to eat than the placebo group (all p <0.05). The 8 and 12 mg arms showed greater improvement than placebo in perceived hunger and disinhibition (the tendency to overeat) at both weeks 24 and 36. Dietary restraint, meaning conscious efforts to limit eating, rose more than with placebo only in the 12 mg arm at week 36. At week 36, less perceived hunger, less disinhibition and more dietary restraint each went along with more weight loss (r = 0.28, r = 0.36 and r = 0.31).
What it doesn’t show
These were exploratory questionnaire results based on what participants reported themselves, and the links to weight loss came from post hoc correlations, which show an association, not cause. Differences between retatrutide and dulaglutide were less consistent than those against placebo.
The paper
Kanu et al. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study. Diabetes Obes Metab. 2025.
The compound
More studies on Retatrutide
- Retatrutide: systolic blood pressure down 6.79 mmHg in meta-analysisMeta-analysis · people · 2026
- Retatrutide: top odds of 15% or more weight loss across 19 trialsMeta-analysis · people · 2025
- Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trialsRandomized trial · people · 2026
- Retatrutide: HbA1c down up to 1.94% in TRANSCEND-T2D-1Randomized trial · people · 2026
- Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1Randomized trial · people · 2026
- Retatrutide: 26.1% fat mass loss at 36 weeks in type 2 diabetesRandomized trial · people · 2025
- Every study on Retatrutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.